In Vitro Screening for Seizure Liability Using Microelectrode Array Technology

Cyprotex have recently published a comprehensive paper in Toxicological Sciences pertaining to the eCiphr®Neuro assay which utilizes microelectrode array (MEA) technology and cryopreserved rat cortical neurons for the prediction of seizure liability and neurotoxicity.  Drug-induced seizure liabilities are a significant factor in compound attrition during the drug discovery process.  However, these liabilities are difficult to detect with typical cell-based endpoint toxicity assays due to their inability to detect disruptions in normal neural network activity.  Cyprotex have developed a high-throughput highly sensitive model for screening compounds based on changes in 12 electrophysiological parameters that accurately assess effects on neural network activity.  Furthermore, we have identified two distinct patterns of change (phenotypes) associated with known seizurogenic compounds that cover a wide variety of chemical classes and targets.  Although we have tested and accurately assessed a significant number of compounds and chemicals for validation purposes and for clients, we chose to focus on a set of 20 compounds to report on for this publication including 15 proconvulsant compounds, 3 negative control compounds and 2 neurotoxic compounds.  Our model accurately predicted the CNS effects for 19 of the 20 compounds. Click here to learn more.

Cyprotex are at the forefront of utilizing MEA technology and experts in analyzing and interpreting the complex data generated by this platform.  We have extensive experience in several different cell types with MEAs including rat cortical neurons, rat hippocampal neurons and various iPSC-derived neurons and stem cell-derived neurons.

Find out more about investigating in vitro neuronal activity using MEA.

This website is intended to assist industry participants, customers and employees to understand Cyprotex's global operations and ambitions.